Zofin is under clinical development by Organicell Regenerative Medicine and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zofin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zofin under development for the treatment of severe acute respiratory syndrome (SARS) caused by the influenza infection, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), post-acute sequelae of covid 2019 (PASC or long covid), heart failure with preserved ejection fraction, chronic obstructive pulmonary disease (COPD) and knee osteoarthritis. The therapeutic candidate comprises of amniotic fluid-derived chemokines, cytokines growth factors, extracellular vesicles and hyaluronic acid.
For a complete picture of Zofin’s drug-specific PTSR and LoA scores, buy the report here.